Genes Reveal How Drugs Move Through the Body; Communities Decide Where Data May Go: A New Path for Māori Precision Medicine

If the mainstream vision of precision medicine could be condensed into one sentence, it would be: 'More data means more precise care.' That sounds reasonable—even technologically progressive. But where the data come from, who authorizes their use, who safeguards them, and who decides how far they may travel are often not discussed with the same seriousness. In practice, many precision-medicine projects therefore collect first, analyze first, and publish first, then patch in governance and cultural considerations later. Indigenous communities know this model well: it closely resembles earlier research-collection practices, except that DNA and electronic health records have replaced plants, crafts, and oral histories as the samples.

What Matters Most About the Māori Case Is Not the Technology, but the Starting Point

The 2026 Māori pharmacogenomics study published in the Journal of Community Genetics matters not only because it examines CYP2C19, a gene involved in metabolizing many drugs. It also begins with community participation and governance design instead of treating the community as a group to be informed only after the research is complete. Through hui, local healthcare partnerships, and sustained communication, the study built relationships for participation. In other words, it did not assume in advance that the data could be collected; it first addressed who has the right to explain, who has the right to ask questions, and who may continue to hold reservations.

This approach may appear slow, but it illustrates an often-overlooked point: if precision medicine is to be genuinely 'precise', it must understand not only the mechanisms linking genes and drugs, but also the relationships linking data and communities. For Māori, genetic information is not simply an individual's medical record. It also implicates whakapapa—family connections, ancestral lineages, and responsibilities to the community. Researchers who treat DNA only as highly sensitive data that an individual may authorize underestimate its collective significance.

Combining Genetic and Prescription Data Can Deliver Real Clinical Value

The study asks a practical technical question: if clinicians know in advance that a person metabolizes a particular drug more slowly or quickly, could they prescribe more precisely, reduce adverse effects, and improve treatment outcomes? By analyzing participants' genetic variants alongside prescription records, the study indicated that some clinical situations might warrant dose adjustments or alternative medications based on genetic information. That is an important signal for clinical care. If precision medicine can reduce trial and error and prevent unnecessary adverse effects, patients stand to benefit.

Precisely because these data are valuable, governance cannot be simplified. Once they are standardized and integrated into platforms, they can easily travel beyond their original scope. Data collected today for pharmacogenomics research may tomorrow be used for large-scale risk analysis, insurance assessments, partnerships with pharmaceutical companies, or other secondary purposes. Without clear boundaries, even a well-intentioned study can change as its data circulate through institutions.

Dynamic Consent Matters Because a Single Click Is Not Valid Forever

Many research and healthcare systems still prefer a model of one-time consent followed by long-term use. It is administratively convenient but often ethically crude. Dynamic consent is gaining attention because it recognizes that people's understanding changes, research purposes expand, and data may flow farther than originally imagined; participants should retain an ongoing right to adjust their consent.

For Indigenous communities, this is even more important. Data governance is not merely a matter of individual authorization. It also concerns whether a community continues to trust the research team, accepts new directions of use, and believes the findings will return with explanation and safeguards. Consent, in other words, should be a relationship rather than a form. If the relationship changes while the form continues to authorize indefinite use, that may be legally convenient, but it is not ethically respectful.

The dynamic-consent and kaitiakitanga approach presented in the Māori study fills a gap often found in modern healthcare. Health-information systems seek integration and reuse; communities emphasize stewardship, responsibility, and the ability to withdraw consent. These priorities are not incompatible. They must be designed together.

Data Sovereignty Is Not an Obstacle to Science; It Gives Science a More Reliable Social Foundation

Critics of Indigenous data sovereignty often make a seemingly pragmatic objection: if medical research encounters barriers at every turn, will innovation slow down? The question itself contains a bias. It assumes that frictionless data flows are normal and that Indigenous governance requirements are an added obstacle. In fact, research without legitimacy or trust is not mature innovation. At most, it is technology moving quickly while ethics struggles to catch up.

The purpose of data sovereignty is not to stop research, but to change the conditions under which it proceeds. Research can still be conducted, but it must answer: Who safeguards the data? Who decides on secondary uses? How are commercial partnerships disclosed? How do findings return to the community? Who is accountable if the research creates risk? Taking these questions seriously does not weaken science; it gives science greater public credibility.

Taiwan should consider these issues early in the governance of Indigenous health data. Electronic health records, health platforms, genomic analysis, and AI models are expanding rapidly here as well. Without community-centered governance principles established now, another form of knowledge extraction may follow: not removing knowledge from communities, but moving bodily data, population data, and cultural context beyond the authority of those entitled to decide.

Two-Eyed Seeing Here Is Not a Compromise, but Precision Through Both Lenses

Viewed through Two-Eyed Seeing, this case is highly instructive. The biomedical lens shows the importance of genotype, enzyme metabolism, drug response, and analysis of electronic health records. The Indigenous-governance lens reminds us that a sample is not an isolated object, data are not resources detached from relationships, and research cannot pretend to stand outside power. With both eyes open, we see not only more precise prescribing, but also a more exacting ethical framework.

Many institutions describe Two-Eyed Seeing as 'fusion' or 'integration.' What is often needed, however, is not to flatten two knowledge systems into one, but to allow each to retain its integrity while they jointly determine how to work together. Māori pharmacogenomics is noteworthy because it does not treat tikanga as decoration for community outreach; it places tikanga within the research design, shaping consent, governance, and trust.

Conclusion: Precision Medicine Cannot Pair Precise Genetics with Coarse Governance

As medicine enters an era of genetics and AI, we do need better tools, finer stratification, and faster analysis. But if data governance still relies on one-time authorization, indefinite extraction, centralized platforms, and the absence of communities, then 'precision medicine' merely refines the technology without distributing power more fairly.

The true value of the Māori case is not that it offers a template for simple replication, but that it reminds us technology never advances alone: it always moves through institutions and cultures. Genes can tell us how drugs move through the body; communities remind us where data should—and should not—go. Only when both are taken seriously can precision medicine avoid becoming another politely conducted extraction project and instead become a more trustworthy form of public healthcare.

From Research Back to Clinical Care: Trust Is Not an Ancillary Benefit, but a Condition of Effectiveness

Many medical innovations treat 'community trust' as an ancillary benefit—good to have, but not essential. In Indigenous health, however, trust is itself a condition of effectiveness. If patients and families do not believe their data will be used responsibly, researchers will address concerns, or results will return to the community, participation, follow-up, clinical translation, and policy implementation all suffer. Governance is therefore not merely an ethical threshold; it is part of research quality.

The lesson for Taiwan is clear: future work involving Indigenous communities in precision medicine, rare-disease research, population-health databases, or AI health models cannot wait until after a project begins to hold an information session. A better approach is to include community representatives, cultural workers, frontline healthcare professionals, and data-governance experts in the design stage, so that how data are collected, governed, and returned is agreed from the outset. When communities are not signatories at the end but co-designers from the beginning, precision medicine has a better chance of moving beyond an extractive model.

Further Reading and Data Sources

• Journal of Community Genetics: Māori pharmacogenomics in primary care｜Verification considerations: study title, authors, sample size, genetic loci, main findings, and research limitations.
• Te Mana Raraunga: Māori Data Sovereignty Network｜Verification considerations: principles of Māori data sovereignty, whakapapa, and connections to data governance.
• Global Indigenous Data Alliance: CARE Principles｜Verification considerations: how to apply CARE principles in medical and genetic data contexts.
• World Health Organization: Genomics and precision public health｜Verification considerations: WHO's foundational explanation of genomics, personalized medicine, and public health applications.
• National Institutes of Health: All of Us Research Program｜Verification considerations: how large-scale health databases handle participant consent and data use statements; serves as a comparative case.
• PubMed: pharmacogenomics and Indigenous health (keyword search)｜Verification considerations: extended literature discussing Indigenous Peoples communities, pharmacogenomics, and research ethics.